DrugPatentWatch Database Preview
Investigational Drug Information for CUDC-907
Email this page to a colleague
What is the development status for investigational drug CUDC-907?
CUDC-907 is an investigational drug.
There have been 13 clinical trials for CUDC-907.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 22nd 2016.
The most common disease conditions in clinical trials are Lymphoma, Neoplasms, and Head and Neck Neoplasms. The leading clinical trial sponsors are Curis, Inc., National Cancer Institute (NCI), and The Leukemia and Lymphoma Society.
There are one hundred and seventy-five US patents protecting this investigational drug and two international patents.
Summary for CUDC-907
| US Patents | 175 |
| International Patents | 2,039 |
| US Patent Applications | 619 |
| WIPO Patent Applications | 498 |
| Japanese Patent Applications | 215 |
| Clinical Trial Progress | Phase 2 (2016-12-22) |
| Vendors | 56 |
Recent Clinical Trials for CUDC-907
| Title | Sponsor | Phase |
|---|---|---|
| Fimepinostat in Treating Brain Tumors in Children and Young Adults | Cannonball Kids' Cancer Foundation | Early Phase 1 |
| Fimepinostat in Treating Brain Tumors in Children and Young Adults | Curis, Inc. | Early Phase 1 |
| Fimepinostat in Treating Brain Tumors in Children and Young Adults | Pacific Pediatric Neuro-Oncology Consortium | Early Phase 1 |
Clinical Trial Summary for CUDC-907
Top disease conditions for CUDC-907
Top clinical trial sponsors for CUDC-907
US Patents for CUDC-907
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| CUDC-907 | ⤷ Try it Free | Substituted thiohydantoin derivatives as androgen receptor antagonists | Janssen Pharmaceutica NV (Beerse, BE) | ⤷ Try it Free |
| CUDC-907 | ⤷ Try it Free | Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity | The University of North Carolina at Chapel Hill (Chapel Hill, NC) | ⤷ Try it Free |
| CUDC-907 | ⤷ Try it Free | Treatment of ophthalmic conditions by selectively removing senescent cells from the eye | Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN) | ⤷ Try it Free |
| CUDC-907 | ⤷ Try it Free | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (Seattle, CA) | ⤷ Try it Free |
| CUDC-907 | ⤷ Try it Free | Heterocyclic estrogen receptor modulators and uses thereof | Genentech, Inc. (South San Francisco, CA) | ⤷ Try it Free |
| CUDC-907 | ⤷ Try it Free | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers | Immunomedics, Inc. (Morris Plains, NJ) | ⤷ Try it Free |
| CUDC-907 | ⤷ Try it Free | Compounds and combinations for the treatment of HIV | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Try it Free |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for CUDC-907
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| CUDC-907 | Argentina | AR107432 | 2036-01-11 | ⤷ Try it Free |
| CUDC-907 | Australia | AU2017207268 | 2036-01-11 | ⤷ Try it Free |
| CUDC-907 | Australia | AU2019203280 | 2036-01-11 | ⤷ Try it Free |
| CUDC-907 | Australia | AU2021201018 | 2036-01-11 | ⤷ Try it Free |
| CUDC-907 | Brazil | BR112018014015 | 2036-01-11 | ⤷ Try it Free |
| CUDC-907 | Canada | CA3010509 | 2036-01-11 | ⤷ Try it Free |
| CUDC-907 | China | CN108473471 | 2036-01-11 | ⤷ Try it Free |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
